DaVita Projects Q3 EPS Growth of 50.6% YoY to $3.78 with Forward P/E at 12.1
Question
DaVita Projects Q3 EPS Growth of 50.6% YoY to $3.78 with Forward P/E at 12.1
Direct answer
Dialysis provider DaVita is heading into its third-quarter earnings release with consensus expectations pointing to $3.78 per share, reflecting a 50.6% increase over the prior year. The performance follows operational efficiencies across outpatient treatment centers. The equity trades at a forward price-to-earnings ratio of 12.1, representing a substantial discount to the broader medical services peer multiple of 19.68. Pricing realization per treatment and patient volume metrics will determine post-earnings valuation revisions. — bullish pressure on DVA.
- Original publisher
- Market Ontology
- Evidence through
- 2026-10-04
- Published
- 2026-10-20
- Revision
- 1 · 2026-10-20
Cite as: Market Ontology, “DaVita Projects Q3 EPS Growth of 50.6% YoY to $3.78 with Forward P/E at 12.1”, revision 1, evidence through 2026-10-04. https://marketontology.com/catalysts/2026-10-04/davita-projects-q3-eps-growth-of-50-6-yoy-to-3-78-with-forward-p-e-at-12-1-61177b
| Asset | Direction | Timeframe | Channel | Score |
|---|---|---|---|---|
| DVA | ▲Bull | 1–4 weeks | Catalyst Driven | 70 |
DaVita Projects Q3 EPS Growth of 50.6% YoY to $3.78 with Forward P/E at 12.1
Dialysis provider DaVita is heading into its third-quarter earnings release with consensus expectations pointing to $3.78 per share, reflecting a 50.6% increase over the prior year. The performance follows operational efficiencies across outpatient treatment centers. The equity trades at a forward price-to-earnings ratio of 12.1, representing a substantial discount to the broader medical services peer multiple of 19.68. Pricing realization per treatment and patient volume metrics will determine post-earnings valuation revisions. — bullish pressure on DVA.
Dialysis provider DaVita is heading into its third-quarter earnings release with consensus expectations pointing to $3.78 per share, reflecting a 50.6% increase over the prior year. The performance follows operational efficiencies across outpatient treatment centers. The equity trades at a forward price-to-earnings ratio of 12.1, representing a substantial discount to the broader medical services peer multiple of 19.68. Pricing realization per treatment and patient volume metrics will determine post-earnings valuation revisions.
- SummaryDialysis provider DaVita is heading into its third-quarter earnings release with consensus expectations pointing to $3.78 per share, reflecting a 50.6% increase over the prior year. The performance follows operational efficiencies across outpatient treatment centers. The equity trades at a forward price-to-earnings ratio of 12.1, representing a substantial discount to the broader medical services peer multiple of 19.68. Pricing realization per treatment and patient volume metrics will determine post-earnings valuation revisions.
- DVADirect directional exposure
Illustrative, not advice
- Crowded positioning may already reflect the move
- Counter-catalyst could neutralize the thesis before window closes
- DVA closes below pre-catalyst level on rising volume
- Catalyst narrative is officially walked back or contradicted
- Cross-asset confirmation (rates / FX / vol) reverses direction
- DVA price vs. pre-event level
- DVA volume vs. 20-day average
What happened next
Price follow-up pending — no stored daily closes for these assets yet.
Closing prices from stored daily bars; returns measured from the last close on or before the event date. Not a recommendation.
No verifiable public source recorded for this card.
Related catalysts
- 2026-10-11DaVita Projects 50.6% Quarterly EPS Growth at 12.15x Forward Earnings MultipleDVA
- 2026-10-11DaVita Outperforms S&P 500 on Projected 50.6% Dialysis EPS ExpansionDVA
- 2026-10-11DaVita Outperforms S&P 500 on Projected 50.6% Dialysis EPS ExpansionDVA XLV+3.45%
- 2026-10-11DaVita Projects 50.6% Quarterly EPS Growth at 12.15x Forward Earnings MultipleDVA
- 2026-10-10DaVita Outpaces S&P 500 on Forecast 50.6 Percent Quarterly EPS GrowthDVA SPY-1.97%
- 2026-10-10DaVita Gains as Forward P/E Holds at 12.15x Against 50.6% Projected EPS GrowthDVA
- 2026-10-10DaVita Gains as Forward P/E Holds at 12.15x Against 50.6% Projected EPS GrowthDVA
- 2026-10-10DaVita Gains 1.3% to $179.25 with Q3 EPS Projected Up 50.6% YoYDVA
See today's live cards
Public pages are published 24 hours after the product shows them. Desk shows every catalyst, event and causal reading as it happens, mapped to your holdings.